TIDMDNL

RNS Number : 8540L

Diurnal Group PLC

15 September 2021

15 September 2021

Diurnal Group plc

("Diurnal" or the "Company")

Director Dealings

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following Directors' dealing:

Richard Bungay, Chief Financial Officer, purchased 19,386 Ordinary Shares at a price of 54.095 pence per Ordinary Share.

Following the transaction, the total beneficial interest of Richard Bungay is 253,578 Ordinary Shares, representing 0.15% of the total voting rights.

Details of the full notifications received by the Company are set out below:

 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                  Richard Bungay 
      ------------------------------------  ----------------------------------------- 
 2     Reason for the notification 
      ------------------------------------------------------------------------------- 
 a)    Position/status                       Chief Financial Officer 
      ------------------------------------  ----------------------------------------- 
 b)    Initial notification                  Initial notification 
        /Amendment 
      ------------------------------------  ----------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------------- 
 a)    Name                                  Diurnal Group plc 
      ------------------------------------  ----------------------------------------- 
 b)    LEI                                   213800I2HNUNZN1LDH29 
      ------------------------------------  ----------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ------------------------------------------------------------------------------- 
 a)    Description of the                    Ordinary shares of 5 pence each in 
        financial instrument,                 Diurnal Group plc 
        type of instrument 
 
       Identification code                   GB00BDB6Q760 
 
 b)    Nature of the transaction             Purchase of ordinary shares 
      ------------------------------------  ----------------------------------------- 
 c)    Price(s) and volume(s) 
                                             --------------------  ---------------- 
                                              Price(s)              Volume(s) 
                                             --------------------  ---------------- 
    GBP0.54095                                                      19,386 
   --------------------------------------------------------------  ---------------- 
 
 d)    Aggregated information 
 
  - Aggregated volume                   As above 
 
  - Price 
 
 e)    Date of the transaction               15 September 2021 
      ------------------------------------  ----------------------------------------- 
 f)    Place of the transaction              XLON 
      ------------------------------------  ----------------------------------------- 
 
 
 For further information, please visit www.diurnal.co.uk or 
  contact: 
 
                                                   +44 (0)20 3727 
 Diurnal Group plc                                  1000 
 Martin Whitaker, Chief Executive Officer 
 Richard Bungay, Chief Financial Officer 
 
 Panmure Gordon (UK) Limited (Nominated Adviser    +44 (0)20 7886 
  and Sole Broker)                                  2500 
 Corporate Finance: Freddy Crossley, Emma Earl 
 Corporate Broking: Rupert Dearden 
 
                                                   +44 (0)20 3727 
 FTI Consulting (Media and Investor Relations)      1000 
 Simon Conway 
 Victoria Foster Mitchell 
 Alex Davis 
 

Notes to Editors

About Diurnal Group plc

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFIFLTARIELIL

(END) Dow Jones Newswires

September 15, 2021 04:16 ET (08:16 GMT)

Diurnal (LSE:DNL)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Diurnal.
Diurnal (LSE:DNL)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Diurnal.